Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7179464 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7182113 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8915178 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7448721 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7188747 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL8852466 | 1.00 | CYP3A4 (0.55) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL893383 | 0.86 | CYP3A4 (0.55) | CYP3A4TDP1CYP2D6CYP2C19 | |
| SCHEMBL893198 | 0.86 | CYP3A4 (0.55) | CYP3A4TDP1CYP2D6CYP2C19 | |
| SCHEMBL4246828 | 0.85 | CYP3A4 (0.52) | CYP3A4TDP1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4677833 | 0.85 | CYP3A4 (0.61) | CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6667404-B2 | Carbamylation of 1-amino group of 1,4-amino-3-hydroxybutane derivative with an organocarbonate containing thiazolyl, oxazolyl, isoxazolyl or isothiazolyl substituent | ABBOTT LABORATORIES | 2003-12-23 | — | — | US | disclosed |
| US-20030195362-A1 | Retroviral protease inhibiting compounds | KEMPF DALE J (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1302468-A1 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6531610-B1 | Intermediate acylating carbonate | ABBOTT LABORATORIES | 2003-03-11 | — | — | US | disclosed |
| EP-0727419-B1 | Intermediates for the preparation of retroviral protease inhibiting compounds | ABBOTT LAB (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1090914-A2 | Processes and intermediates for manufacturing retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6150530-A | AMIDATION OF AMINE WITH ACID | ABBOTT LABORATORIES (US) | 2000-11-21 | — | — | US | disclosed |
| US-6017928-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2000-01-25 | — | — | US | disclosed |
| US-5892052-A | Process for making retroviral protease inhibiting compounds | ABBOTT LABORTORIES (US) | 1999-04-06 | — | — | US | disclosed |
| US-5886036-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1999-03-23 | — | — | US | disclosed |
| US-5591860-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| US-5583232-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583233-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5580984-A | 1-OXA-3-AZA-2-BORINE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| US-5565418-A | PREPARING CARBAMATE INTERMEDIATES BY REACTING SUBSTITUTED HYDROXYDIAMINE COMPOUND WITH ONE AMINE PROTECTED WITH ACTIVATED ACYLATING AGENT, DEPROTECTING | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0674513-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195362-A1 | Retroviral protease inhibiting compounds | PREP, SERPINB1, PRSS1 | CYP3A4 1658/4885TDP1 691/4885CYP1A2 3115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.